ES2951259T3 - Aumento del rendimiento de las partículas similares a virus en las plantas - Google Patents

Aumento del rendimiento de las partículas similares a virus en las plantas Download PDF

Info

Publication number
ES2951259T3
ES2951259T3 ES12836545T ES12836545T ES2951259T3 ES 2951259 T3 ES2951259 T3 ES 2951259T3 ES 12836545 T ES12836545 T ES 12836545T ES 12836545 T ES12836545 T ES 12836545T ES 2951259 T3 ES2951259 T3 ES 2951259T3
Authority
ES
Spain
Prior art keywords
protein
plant
influenza
sec
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12836545T
Other languages
English (en)
Spanish (es)
Inventor
Marc-Andre D'aoust
Manon Couture
Louis-Philippe Vezina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicago Inc
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Application granted granted Critical
Publication of ES2951259T3 publication Critical patent/ES2951259T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES12836545T 2011-09-30 2012-09-28 Aumento del rendimiento de las partículas similares a virus en las plantas Active ES2951259T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541780P 2011-09-30 2011-09-30
PCT/CA2012/050681 WO2013044390A1 (en) 2011-09-30 2012-09-28 Increasing virus-like particle yield in plants

Publications (1)

Publication Number Publication Date
ES2951259T3 true ES2951259T3 (es) 2023-10-19

Family

ID=47994080

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12836545T Active ES2951259T3 (es) 2011-09-30 2012-09-28 Aumento del rendimiento de las partículas similares a virus en las plantas

Country Status (27)

Country Link
US (1) US11155581B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2760882B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6248040B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101974017B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN116218900A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012315421C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014007474A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2850407C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2760882T5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2951259T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI2760882T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20230695T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE062759T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL231587B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014CN03077A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX358883B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY184072A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ622731A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014500640A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2760882T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2760882T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2682752C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG11201400712VA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2760882T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI700368B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013044390A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201403059B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
HUE062759T2 (hu) 2011-09-30 2023-12-28 Medicago Inc Vírusszerû részecske hozamának növelése növényekben
MX376138B (es) * 2013-03-28 2025-03-07 Medicago Inc Produccion de particulas similares a virus de influenza en plantas.
WO2015103704A1 (en) 2014-01-10 2015-07-16 Medicago Inc. Cpmv enhancer elements
CN106460005B (zh) * 2014-03-27 2020-01-03 莫迪卡戈公司 修饰的cpmv增强子元件
JP7423875B6 (ja) * 2018-03-14 2024-03-15 メディカゴ インコーポレイテッド 植物発現エンハンサ
MX2020013957A (es) * 2018-06-27 2021-03-09 Medicago Inc Mutantes de hemaglutinina del virus de la influenza.
BR112021017899A2 (pt) * 2019-03-14 2021-12-21 Medicago Inc Intensificador de expressão vegetal endógeno
WO2021236908A2 (en) * 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5805417A (en) 1995-10-13 1998-09-08 Hitachi, Ltd. Heat dissipation structure in a portable computer including a heat dissipation block extending from a heat dissipation plate through a first circuit board to a CPU on a second circuit board
WO2000020557A2 (en) 1998-10-07 2000-04-13 Boyce Institute For Plant Research At Cornell University Gemini virus vectors for gene expression in plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
RU2164148C1 (ru) * 2000-08-09 2001-03-20 Петров Рэм Викторович Вакцина против вируса гриппа и способ ее получения
KR20060035596A (ko) * 2003-05-05 2006-04-26 보이스 톰슨 인스터튜트 포 플랜트 리서치 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포
BRPI0410342A (pt) 2003-05-05 2006-06-20 Dow Agrosciences Llc composições imunoprofiláticas e terapêuticas estáveis derivadas de células vegetais transgênicas e processos para produção
PL2374892T3 (pl) * 2005-04-29 2018-06-29 University Of Cape Town Ekspresja białek wirusa w roślinach
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
AU2006304640B2 (en) * 2005-10-18 2012-10-11 Novavax, Inc. Functional influenza virus like particles (VLPs)
WO2007051036A2 (en) * 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
EP1991571A2 (en) 2006-02-16 2008-11-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral agents and vaccines against influenza
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2008054535A2 (en) 2006-05-11 2008-05-08 Novavax, Inc. Novel influenza m2 vaccines
EP2029755A1 (en) 2006-05-22 2009-03-04 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
KR20090027216A (ko) * 2006-06-16 2009-03-16 다우 아그로사이언시즈 엘엘씨 조류 인플루엔자 헤마글루티닌의 신규한 dna 서열, 벡터, 및 단백질
US8697088B2 (en) 2007-05-25 2014-04-15 Novavax, Inc. VLPs derived from cells that do not express a viral matrix or core protein
CN104962579A (zh) 2007-06-15 2015-10-07 麦迪卡格公司 修饰植物中的糖蛋白产生
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2238253B1 (en) 2007-11-27 2012-09-12 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
KR101956910B1 (ko) 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs)
WO2010003235A1 (en) 2008-07-08 2010-01-14 Medicago Inc. Soluble recombinant influenza antigens
MY161965A (en) * 2008-07-18 2017-05-15 Medicago Inc New influenza virus immunizing epitope
AU2009285667B2 (en) 2008-08-27 2015-05-28 Arizona Board Of Regents For And On Behalf Of Arizona State University A DNA replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
IN2012DN00650A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-06-24 2015-06-12 Medicago Inc
FR2947875B1 (fr) 2009-07-10 2011-07-08 Raymond A & Cie Dispositif de fixation a elements de fixation multiples dont l'un est flottant
WO2011011390A1 (en) 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
DK2480560T3 (en) 2009-09-22 2018-04-16 Medicago Inc PROCEDURE FOR THE PREPARATION OF PLANT DERIVATIVE PROTEINS
EP2536428B1 (en) 2010-02-18 2018-12-05 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
US10226527B2 (en) 2010-10-04 2019-03-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
PL220281B1 (pl) 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
HUE062759T2 (hu) 2011-09-30 2023-12-28 Medicago Inc Vírusszerû részecske hozamának növelése növényekben
US11390878B2 (en) * 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
JP6205359B2 (ja) 2012-07-23 2017-09-27 有限会社生物資源研究所 ワクチン
MX376138B (es) 2013-03-28 2025-03-07 Medicago Inc Produccion de particulas similares a virus de influenza en plantas.

Also Published As

Publication number Publication date
CA2850407C (en) 2021-11-23
CA2850407A1 (en) 2013-04-04
WO2013044390A1 (en) 2013-04-04
NZ622731A (en) 2016-04-29
TWI700368B (zh) 2020-08-01
SG10201708052XA (en) 2017-11-29
PT2760882T (pt) 2023-08-07
IL231587A0 (en) 2014-05-28
IN2014CN03077A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-03
EP2760882B1 (en) 2023-05-24
DK2760882T3 (da) 2023-07-03
EP3626733A1 (en) 2020-03-25
AU2012315421C1 (en) 2019-12-05
MX2018006627A (es) 2020-11-12
KR101974017B1 (ko) 2019-04-30
EP3626733B1 (en) 2024-01-24
US20150104480A1 (en) 2015-04-16
RU2014116371A (ru) 2015-11-10
MX358883B (es) 2018-08-31
KR20140068260A (ko) 2014-06-05
ZA201403059B (en) 2019-07-31
PH12014500640A1 (en) 2014-05-05
RU2682752C2 (ru) 2019-03-21
MY184072A (en) 2021-03-17
JP6248040B2 (ja) 2017-12-13
TW201329235A (zh) 2013-07-16
DK2760882T5 (da) 2024-06-24
EP2760882A1 (en) 2014-08-06
CN103930435A (zh) 2014-07-16
HUE062759T2 (hu) 2023-12-28
SG11201400712VA (en) 2014-04-28
PL2760882T3 (pl) 2023-09-11
BR112014007474A2 (pt) 2017-04-04
HRP20230695T1 (hr) 2023-12-22
EP2760882A4 (en) 2015-06-10
AU2012315421A1 (en) 2014-04-10
CN116218900A (zh) 2023-06-06
MX2014003776A (es) 2014-08-21
SI2760882T1 (sl) 2023-10-30
JP2014530006A (ja) 2014-11-17
US11155581B2 (en) 2021-10-26
FI2760882T3 (fi) 2023-07-17
HK1200179A1 (en) 2015-07-31
IL231587B (en) 2020-06-30
AU2012315421B2 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
US10272148B2 (en) Chimeric influenza virus-like particles comprising hemagglutinin
JP5990207B2 (ja) ヘマグルチニンを発現するトランスジェニック植物において産生された組換え型インフルエンザウイルス様粒子(vlp)
ES2525177T3 (es) Partículas similares al virus de la influenza (VLP) que comprenden hemaglutinina
ES2428384T3 (es) Partículas similares al virus de la influenza (VLP) que contienen hemaglutinina producida dentro de una planta
ES2951259T3 (es) Aumento del rendimiento de las partículas similares a virus en las plantas
AU2009270404B2 (en) New influenza virus immunizing epitope
ES2803508T3 (es) Producción de partículas similares al virus de la gripe en plantas
US11390878B2 (en) Increasing protein yield in plants
RU2569195C9 (ru) Химерные вирусоподобные частицы, содержащие гемагглютинин, сходные с частицами вируса гриппа
HK1200179B (en) Increasing virus-like particle yield in plants
BRPI0906960B1 (pt) Ácido nucleico compreendendo uma sequência de nucleotídeos codificando uma hemaglutinina do vírus de influenza (ha), partículas semelhantes a vírus (vlps), seu método de produção, composição e uso dos mesmos